Related Experiment Video

Updated: Aug 15, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Teratogens as anti-cancer drugs

Mikhail V Blagosklonny1

  • 1Cancer Center, Ordway Research Institute, Albany, New York 12208, USA. mblagosklonny@ordwayresearch.org

Cell Cycle (Georgetown, Tex.)
|November 1, 2005
PubMed

Insights

Certain plant-derived teratogens, like cyclopamine, selectively target embryonic pathways reactivated in cancer. This research explores their potential in cancer therapy by inhibiting the Hedgehog/Gli (Hh/Gli) pathway.

Area of Science:

  • Developmental Biology
  • Pharmacology
  • Oncology

Background:

  • Most anticancer drugs are teratogens due to targeting vital cellular functions.
  • Some plants produce selective teratogens that disrupt embryonic development by targeting specific signaling pathways.

Purpose of the Study:

  • To explore the potential and limitations of using teratogens in cancer therapy.
  • To investigate selective teratogens that target embryonic pathways reactivated in cancer cells.
  • To link morning sickness, embryonic pathways, poisonous plants, and anticancer teratogen mechanisms.

Main Methods:

  • Review of existing literature on teratogens, embryonic signaling pathways, and cancer biology.
  • Analysis of the mechanism of action of plant-derived teratogens, such as cyclopamine.
  • Discussion of the potential for selective teratogens to target cancer cells while sparing normal cells.

Main Results:

  • Cyclopamine, a plant-derived teratogen, inhibits the Hedgehog/Gli (Hh/Gli) pathway, causing developmental defects like cyclopia.
  • Selective teratogens theoretically offer a strategy to target cancer cells that reactivate embryonic pathways.
  • The study links diverse concepts including pregnancy-related conditions, developmental biology, and phytochemistry to cancer treatment.

Conclusions:

  • Selective teratogens represent a potential therapeutic avenue in oncology.
  • Further research is needed to understand the full potential and limitations of teratogens in cancer treatment.
  • Combinations of selective teratogens with cytotoxic agents may enhance therapeutic efficacy.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...